XYZAL ORAL SOLUTION Rx
Generic Name and Formulations:
Levocetirizine dihydrochloride 0.5mg/mL.
UCB and Sanofi Aventis
Indications for XYZAL ORAL SOLUTION:
Seasonal allergic rhinitis (for patients ≥2yrs old). Perennial allergic rhinitis, chronic idiopathic urticaria (for patients ≥6 months old).
2.5mg–5mg once daily in the PM. Renal dysfunction: CrCl 50–80mL/min: 2.5mg once daily; CrCl 30–50mL/min: 2.5mg every other day; CrCl 10–30mL/min: 2.5mg twice per week (every 3–4 days); CrCl <10mL/min or hemodialysis: contraindicated.
<6 months: not recommended. 6 months–5yrs: max 1.25mg once daily in the PM. 6–11yrs: max 2.5mg once daily in the PM. Renal dysfunction: contraindicated.
End-stage renal disease (CrCl <10mL/min) or hemodialysis. Impaired renal function (<12yrs of age).
Do not exceed recommended dose. Predisposing factors of urinary retention (eg, spinal cord lesion, prostatic hyperplasia). Discontinue if urinary retention occurs. Pregnancy (Cat.B). Nursing mothers: not recommended.
Avoid alcohol, other CNS depressants. May be potentiated by theophylline. Potentiated by ritonavir.
Adults: somnolence, nasopharyngitis/pharyngitis, fatigue, dry mouth. Children: pyrexia, somnolence, cough, epistaxis, diarrhea, constipation, vomiting, otitis media.
Renal (primarily), fecal.
- Nine Factors That Appear to Elevate Alzheimer's Risk
- NSAIDs Linked to Long-Term Colon Cancer Risk Reduction
- Clinical Suspicion Leads to Uncommon Diagnosis in Patient With High Fever
- What a New Study Says About Omega-3s and Brain Health
- Measles and 'Immune Amnesia': Why Vaccination Could Also Prevent Other Diseases